Phagelux, Inc., a biotechnology company focused on the development and commercialization of novel phage and lysin antibacterial products and solutions, has reached an agreement with Johnson & Johnson Consumer, Inc. to collaborate on the development of one or more skin care products. Under the terms of the agreement, Phagelux will be responsible for developing these products utilizing its patented or patent pending technologies and Johnson & Johnson Consumer, Inc. will provide specified...